Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLPT ClearPoint Neuro	$13.44 -2.9%	$11.50	$8.27 ▼ $30.10	$403.07M	1.31	553,469 shs	448,348 shs
CNXU Conexeu Sciences	$11.29 -6.9%	$0.00	$10.87 ▼ $18.79	$285.30M	N/A	93,790 shs	58,391 shs
DCTH Delcath Systems	$11.72 -0.4%	$10.82	$8.12 ▼ $15.57	$404.60M	0.54	530,103 shs	299,613 shs
GUTS Fractyl Health	$0.85 +17.4%	$0.69	$0.38 ▼ $2.45	$134.85M	2.34	1.51 million shs	3.08 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLPT ClearPoint Neuro	-2.89%	+4.27%	+10.25%	+24.56%	+4.59%
CNXU Conexeu Sciences	-6.92%	-25.92%	+1,128,999,900.00%	+1,128,999,900.00%	+1,128,999,900.00%
DCTH Delcath Systems	-0.42%	+9.84%	+0.95%	+24.02%	-26.57%
GUTS Fractyl Health	+17.42%	+25.26%	-10.53%	+80.85%	-62.56%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLPT ClearPoint Neuro	$13.44 -2.9%	$11.50	$8.27 ▼ $30.10	$403.07M	1.31	553,469 shs	448,348 shs
CNXU Conexeu Sciences	$11.29 -6.9%	$0.00	$10.87 ▼ $18.79	$285.30M	N/A	93,790 shs	58,391 shs
DCTH Delcath Systems	$11.72 -0.4%	$10.82	$8.12 ▼ $15.57	$404.60M	0.54	530,103 shs	299,613 shs
GUTS Fractyl Health	$0.85 +17.4%	$0.69	$0.38 ▼ $2.45	$134.85M	2.34	1.51 million shs	3.08 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLPT ClearPoint Neuro	-2.89%	+4.27%	+10.25%	+24.56%	+4.59%
CNXU Conexeu Sciences	-6.92%	-25.92%	+1,128,999,900.00%	+1,128,999,900.00%	+1,128,999,900.00%
DCTH Delcath Systems	-0.42%	+9.84%	+0.95%	+24.02%	-26.57%
GUTS Fractyl Health	+17.42%	+25.26%	-10.53%	+80.85%	-62.56%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLPT ClearPoint Neuro	2.33	Hold	$18.00	33.93% Upside
CNXU Conexeu Sciences	0.00	N/A	N/A	N/A
DCTH Delcath Systems	2.43	Hold	$22.50	91.98% Upside
GUTS Fractyl Health	2.40	Hold	$5.40	535.29% Upside

Current Analyst Ratings Breakdown

Latest GUTS, CLPT, CNXU, and DCTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2026	CLPT ClearPoint Neuro	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$16.00
6/4/2026	GUTS Fractyl Health	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
5/12/2026	GUTS Fractyl Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
5/11/2026	DCTH Delcath Systems	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
5/11/2026	DCTH Delcath Systems	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
5/8/2026	CLPT ClearPoint Neuro	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$16.00
4/24/2026	GUTS Fractyl Health	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
4/20/2026	CLPT ClearPoint Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
3/26/2026	GUTS Fractyl Health	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
3/18/2026	CLPT ClearPoint Neuro	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $20.00

(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLPT ClearPoint Neuro	$36.97M	10.90	N/A	N/A	$0.99 per share	13.58
CNXU Conexeu Sciences	N/A	N/A	N/A	N/A	N/A	N/A
DCTH Delcath Systems	$85.23M	4.75	$0.05 per share	225.06	$3.15 per share	3.72
GUTS Fractyl Health	$90K	1,498.36	N/A	N/A	$0.07 per share	12.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLPT ClearPoint Neuro	-$25.54M	-$1.01	N/A	N/A	N/A	-71.57%	-140.96%	-36.98%	8/11/2026 (Estimated)
CNXU Conexeu Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DCTH Delcath Systems	$2.70M	$0.01	1,172.00	N/A	N/A	0.62%	0.51%	0.46%	8/5/2026 (Estimated)
GUTS Fractyl Health	-$140.95M	-$1.29	N/A	N/A	N/A	N/A	-4,053.15%	-96.41%	8/11/2026 (Estimated)

Latest GUTS, CLPT, CNXU, and DCTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2026	Q1 2026	CLPT ClearPoint Neuro	-$0.28	-$0.32	-$0.04	-$0.32	$11.97 million	$12.13 million
5/12/2026	Q1 2026	GUTS Fractyl Health	-$0.17	$0.06	+$0.23	$0.06	N/A	N/A
5/7/2026	Q1 2026	DCTH Delcath Systems	-$0.0971	-$0.03	+$0.0671	-$0.03	$23.51 million	$24.99 million
3/24/2026	Q4 2025	GUTS Fractyl Health	-$0.19	$0.15	+$0.34	-$0.07	N/A	N/A
3/17/2026	Q4 2025	CLPT ClearPoint Neuro	-$0.22	-$0.27	-$0.05	-$0.27	$10.40 million	$10.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLPT ClearPoint Neuro	N/A	N/A	N/A	N/A	N/A
CNXU Conexeu Sciences	N/A	N/A	N/A	N/A	N/A
DCTH Delcath Systems	N/A	N/A	N/A	N/A	N/A
GUTS Fractyl Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLPT ClearPoint Neuro	2.63	5.79	4.88
CNXU Conexeu Sciences	N/A	N/A	N/A
DCTH Delcath Systems	N/A	11.24	10.33
GUTS Fractyl Health	1.41	4.28	4.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLPT ClearPoint Neuro	30.08%
CNXU Conexeu Sciences	N/A
DCTH Delcath Systems	61.12%
GUTS Fractyl Health	N/A

Insider Ownership

Company	Insider Ownership
CLPT ClearPoint Neuro	6.94%
CNXU Conexeu Sciences	N/A
DCTH Delcath Systems	19.36%
GUTS Fractyl Health	8.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLPT ClearPoint Neuro	110	29.99 million	27.91 million	Optionable
CNXU Conexeu Sciences	4	25.27 million	N/A	N/A
DCTH Delcath Systems	60	34.52 million	27.84 million	Optionable
GUTS Fractyl Health	102	158.65 million	145.13 million	N/A

GUTS, CLPT, CNXU, and DCTH Headlines

Recent News About These Companies

Fractyl Health Inc (GUTS) Cleared for RJVA-001 Trial. Let’s Look At Funding

June 12 at 1:04 PM | finance.yahoo.com $https://finance.yahoo.com/sectors/healthcare/articles/fractyl-health-inc-guts-cleared-032359134.html$

Fractyl Health (NASDAQ:GUTS) CEO Harith Rajagopalan Acquires 25,000 Shares

June 12 at 7:34 AM | insidertrades.com

Fractyl Health Stockholders Back Board and Auditor at Meeting

June 11 at 7:11 PM | tipranks.com $https://www.tipranks.com/news/company-announcements/fractyl-health-stockholders-back-board-and-auditor-at-meeting?utm_source=marketbeat.com&utm_medium=referral$

Fractyl Health (NASDAQ:GUTS) CFO Purchases $13,800.00 in Stock

June 10 at 6:26 AM | insidertrades.com

Fractyl Health, Inc. (NASDAQ:GUTS) Given Average Recommendation of "Hold" by Analysts

June 10 at 4:17 AM | americanbankingnews.com

Fractyl Health Highlights One-Year Revita Obesity Results

June 4, 2026 | tipranks.com $https://www.tipranks.com/news/company-announcements/fractyl-health-highlights-one-year-revita-obesity-results?utm_source=marketbeat.com&utm_medium=referral$

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

June 4, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/06/04/3306626/0/en/fractyl-health-reports-positive-one-year-reveal-1-open-label-results-showing-sustained-post-glp-1-weight-maintenance-after-a-single-revita-procedure.html$

Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy

June 1, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/06/01/3304198/0/en/fractyl-health-appoints-mike-zumdahl-as-senior-vice-president-market-access-and-commercial-strategy.html$

Fractyl Health (GUTS) Is Up 14.0% After First GLP-1 Gene Therapy Trial Win And Profit Turnaround

May 16, 2026 | finance.yahoo.com $https://finance.yahoo.com/sectors/healthcare/articles/fractyl-health-guts-14-0-201333416.html$

A Look At Fractyl Health (GUTS) Valuation After New Gene Therapy Trial Approval And First Quarter Net Income

May 14, 2026 | finance.yahoo.com $https://finance.yahoo.com/sectors/healthcare/articles/look-fractyl-health-guts-valuation-131904067.html$

Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

May 14, 2026 | seekingalpha.com $https://seekingalpha.com/article/4904760-fractyl-health-inc-guts-presents-at-bank-of-america-global-healthcare-conference-2026$

Fractyl Health’s Pivotal Year: Inside the Earnings Call

May 13, 2026 | tipranks.com $https://www.tipranks.com/news/company-announcements/fractyl-healths-pivotal-year-inside-the-earnings-call?utm_source=marketbeat.com&utm_medium=referral$

Fractyl Health Inc (GUTS) Q1 2026 Earnings Call Highlights: Pivotal Trial Progress and ...

May 13, 2026 | finance.yahoo.com $https://finance.yahoo.com/news/fractyl-health-inc-guts-q1-050200732.html$

Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript

May 12, 2026 | seekingalpha.com $https://seekingalpha.com/article/4903529-fractyl-health-inc-guts-q1-2026-earnings-call-transcript$

Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

May 12, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/05/12/3293378/0/en/fractyl-health-reports-first-quarter-2026-financial-results-and-business-updates.html$

Fractyl Health Advances RJVA-001 Gene Therapy Trial

May 11, 2026 | tipranks.com $https://www.tipranks.com/news/company-announcements/fractyl-health-advances-rjva-001-gene-therapy-trial?utm_source=marketbeat.com&utm_medium=referral$

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

May 11, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/05/11/3291742/0/en/fractyl-health-authorized-to-initiate-first-in-human-trial-of-rjva-001-in-the-netherlands-first-gene-therapy-candidate-to-enter-clinical-development-for-type-2-diabetes.html$

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

May 5, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/05/05/3287505/0/en/fractyl-health-to-report-first-quarter-2026-financial-results-and-provide-business-updates-on-may-12-2026-and-will-participate-in-an-upcoming-investor-conference.html$

Fractyl Health Earnings Call: Revita Nears Key Pivotal Test

March 27, 2026 | tipranks.com $https://www.tipranks.com/news/company-announcements/fractyl-health-earnings-call-revita-nears-key-pivotal-test?utm_source=marketbeat.com&utm_medium=referral$

Fractyl Health, Inc. common stock (NASDAQ:GUTS) Q4 2025 earnings call transcript

March 26, 2026 | msn.com $https://www.msn.com/en-us/health/other/fractyl-health-inc-common-stock-nasdaqguts-q4-2025-earnings-call-transcript/ar-AA1ZsdpH$

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GUTS, CLPT, CNXU, and DCTH Company Descriptions

ClearPoint Neuro NASDAQ:CLPT

$13.44 -0.40 (-2.89%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$13.53 +0.09 (+0.64%)

As of 06/12/2026 07:33 PM Eastern

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Conexeu Sciences NASDAQ:CNXU

$11.29 -0.84 (-6.92%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$12.24 +0.96 (+8.46%)

As of 06/12/2026 07:45 PM Eastern

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University's right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company's only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix ("ECM") formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the "10 Minute Tissue™" concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration ("FDA") clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.

Delcath Systems NASDAQ:DCTH

$11.72 -0.05 (-0.42%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$11.77 +0.05 (+0.40%)

As of 06/12/2026 07:57 PM Eastern

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Fractyl Health NASDAQ:GUTS

$0.85 +0.13 (+17.42%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$0.86 +0.01 (+0.59%)

As of 06/12/2026 07:59 PM Eastern

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GUTS, CLPT, CNXU, and DCTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GUTS, CLPT, CNXU, and DCTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GUTS, CLPT, CNXU, and DCTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GUTS, CLPT, CNXU, and DCTH Company Descriptions

ClearPoint Neuro NASDAQ:CLPT

Conexeu Sciences NASDAQ:CNXU

Delcath Systems NASDAQ:DCTH

Fractyl Health NASDAQ:GUTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GUTS, CLPT, CNXU, and DCTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GUTS, CLPT, CNXU, and DCTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GUTS, CLPT, CNXU, and DCTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GUTS, CLPT, CNXU, and DCTH Company Descriptions

ClearPoint Neuro NASDAQ:CLPT

Conexeu Sciences NASDAQ:CNXU

Delcath Systems NASDAQ:DCTH

Fractyl Health NASDAQ:GUTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools